Last reviewed · How we verify
INCMGA00012
INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity.
INCMGA00012 is an anti-CTLA-4 monoclonal antibody that blocks immune checkpoint inhibition to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic melanoma, Other solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | INCMGA00012 |
|---|---|
| Also known as | Retifanlimab, PD-1 inhibitor, PD1, retifanlimab |
| Sponsor | Providence Health & Services |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CTLA-4 is an inhibitory receptor on T cells that suppresses immune responses. By blocking CTLA-4, this antibody removes a key brake on T-cell activation, allowing enhanced proliferation and effector function of tumor-infiltrating lymphocytes. This mechanism is designed to potentiate anti-tumor immune responses in cancer patients.
Approved indications
- Advanced or metastatic melanoma
- Other solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Immune-related colitis
- Immune-related hepatitis
- Immune-related pneumonitis
- Fatigue
- Rash
Key clinical trials
- Combination Study of SV-BR-1-GM With Retifanlimab (PHASE1, PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (PHASE1, PHASE2)
- Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (PHASE1)
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (PHASE3)
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma (PHASE1, PHASE2)
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (PHASE2)
- Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |